Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

NCT: NCT07110233 · NOT_YET_RECRUITING

NCT IDNCT07110233
StatusNOT_YET_RECRUITING
Start Date2026-10-01
Completion2029-03-31
SponsorUniversity of California, San Francisco (OTHER)
First posted
Last updated

Brief Summary

This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with unresectable Barcelona clinic liver cancer (BCLC) stage A disease.

Frequently Asked Questions

What is Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma?

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma is a clinical trial registered under NCT07110233. Current status: NOT_YET_RECRUITING.

What is the status of NCT07110233?

The current status of NCT07110233 (Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma) is: NOT_YET_RECRUITING.

When did Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma start?

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma started on 2026-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑